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Abstract. Quinolones are a class of broad-spectrum antibiotics with valuable pharmacological 
properties due to their improved pharmacokinetic properties, particular mechanism of action and 
broad and potent activity; being one of the fastest growing class antibacterial growths in terms of 
therapeutic use and overall benefit. Because of their effectiveness, spectrum of activity, and 
generally good safety profile, fluoroquinolones were used widely for multiple clinical indications 
throughout the world. Although still clinically valuable, fluoroquinolone use has become limited 
in some clinical situations, as bacterial resistance has emerged over time. In the sections that 
follow we review the range of molecular mechanisms that motivate quinolone resistance.  
Keywords: quinolones, antimicrobial resistance, mechanism of action, DNA gyrase, 
topoisomerase IV. 
1. Introduction 
The Quinolones are the first synthetic antibacterial agents used in humans, they are bactericidal, 
they form a class of antibiotics that has taken an important place in the arsenal therapeutic. 
Quinolones owe their discovery to chloroquine research. Laboratory researchers 
Sterling-Winthrop (Rochester, NY) accidentally discovered a product derived from its synthesis 
and endowed with antibacterial properties: 7-chloroquinoline. This molecule has been developed 
to give nalidixic acid (Fig. 1). Currently, more than 10.000 base core derivatives have been 
described [1, 2]. 
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Fig. 1. From chloroquine to nalidixic acid 
The Quinolones are synthetic antibacterial agents comprising two fused aromatic rings, a 
pyridine ring with a 4-ketone function, a 3-carbon carboxylic acid, 1-substituted nitrogen, and the 
second is a heterocycle (pyridine or pyrimidine) or a benzene [3]. 
2. Quinolones classification 
The classification of fluoroquinolones takes into account the antimicrobial spectrum and their 
clinical indications. This classification is a tool for doctors to use when prescribing these drugs or 
evaluating new active ingredients introduced into the market. One drug in each group is similar to 
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an antimicrobial activity. With each successive generation, a large new group of pathogens is 
added to the cover. Quinolones are usually classified into four generations based on their activity 
and spectrum of activity [4]. 
 
Fig. 2. Common structure of quinolones 
2.1. First generation 
In 1962, Lesher G. Y. and his collaborators presented the primary derivative of quinolone, 
nalidixic acid, which has direct action against Gram-negative bacteria and has been utilized to 
treat urinary tract diseases. Within the taking after a long time, a wide extend of products derived 
from common components were synthesized, which might be gathered by: cinoline (cinoxacin), 
pyrido-pyrimidine (pipemidic acid, piromidic acid), naphthyridine (nalidixic corrosive) and 
quinolones (oxolinic acid, miloxacin, tioxacin, etc.). These derivatives, with separated structures, 
have two common pharmacological properties: 
– A fine antibacterial range, extraordinarily planned for Enterobacteriaceae; 
– A pharmacokinetics that permits quick disposal and diminished tissue intrigued, as it were 
permitting them to be utilized as urinary cleaning agents [5]. 
 
Fig. 3. Quinolones of first generation 
The victory of early era quinolones fortified inquire about in this zone, which driven to the 
blend getting, after 1980, of a unused series of compounds with solid antibacterial properties and 
a large range of antibacterial movement that included Gram-positive and Gram negative. 
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2.2. Second generation 
Koga and his collaborators presented Norfloxacin in clinical utilize in 1980, the primary 
quinolone with a fluorine atom substituted within the C-6 position and a C-7 piperazine. 
Norfloxacin was the primary quinolone with expanded antimicrobial action, acting on a wide 
range of Gram-positive and Gram-negative microscopic organisms, counting Pseudomonas 
aeruginosa microorganisms [6]. 
 
Fig. 4. Quinolones of second generation 
Investigate within the field of derivatives with a quinolone structure has driven to modern 
compounds gotten, which have been classified as third and fourth era systemic quinolones, 
generally compelling against Staphylococcus aureus. Their wide antibacterial range incorporates 
anaerobes, Chlamydia and Mycoplasma [7]. 
2.3. Third generation 
Third-generation agents currently include levofloxacin, grepafloxacin, and sparfloxacin. These 
agents are separated into a third class because of their expanded action against gram-positive 
organisms, counting the penicillin-resistant Streptococcus pneumoniae [8]. 
2.4. Fourth generation 
The fourth generation has the taking after common angles: an indistinguishable instrument of 
activity by the restraint of DNA gyrase A subunit, solely chromosomal resistance of microbes and 
certain impacts of comparative microbes: photo-toxicity, neurotoxicity, cartilage harmfulness [9]. 
So far, a huge number of antibacterial substances having a place to the class said over has been 
utilized in medication. Quinolones are utilized when treating urinary tract diseases, respiratory 
tract, intestinal contaminations, ear/nose/throat infections, tissue contaminations and mellow skin, 
meningitis caused by gram-negative microbes and Staphilococci microscopic organisms, 
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infections of the liver and bile channels, sepsis and endocarditis, prophylaxis and surgical diseases 
and on patients with safe lack. 
 
Fig. 5. Quinolones of third generation 
 
Fig. 6. Quinolones of fourth generation 
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3. Mechanism of action and resistance 
3.1. Intra-bacterial penetration 
Gram (+) bacteria lack an outer membrane, with a wall consisting of a thick peptidoglycan. 
The penetration of quinolones is by passive diffusion. 
For bacteria with gram (–), the intrabacterial penetration is done by two ways: 
– The porin pathway: hydrophilic channels in the form of trimers for hydrophilic and small 
quinolones (< 400 dalton) (norfloxacin and ciprofloxacin). 
– The lipopolysaccharide (LPS) pathway: by Mg2 + chelation associated with LPS and 
discovery of hydrophobic zones, hence the penetration of hydrophobic quinolones 
(sparfloxacin) [10]. 
3.2. Mechanisms of quinolone action  
QNs interfere with changes in DNA supercoiling by binding to II or IV. This leads to the 
formation of double-stranded DNA breaks and cell death either in a protein synthesis dependent 
manner or in a manner independent of protein synthesis [11]. They target two parent enzymes 
belonging to the family of topoisomerases II and which are involved in the synthesis of bacterial 
DNA: DNA-gyrase (generally the main target in Gram-negative bacteria) and topoisomerase IV 
(usually the main target in Gram-positive bacteria). 
New fluoroquinolones such as gatifloxacin and moxifloxacin have both activities. DNA 
Gyrase is composed of two GyrA subunits encoded by the gyrA gene and two GyrB subunits 
encoded by the gyrB gene. It introduces a negative supercoiling into the bacterial DNA double 
helix upstream of the replication fork. This activity is essential for the initiation of bacterial DNA 
replication and for transcription [12, 13]. 
Topoisomerase IV has a decatenation activity that allows the separation of replicated 
chromosomes at the end of a replication sequence. It is composed of 4 subunits homologous to 
those of gyrase, two ParC subunits (homologues of GyrA) and two ParE subunits (homologues of 
GyrB) encoded by the genes parC and parE respectively [14]. 
3.3. Mechanisms of quinolone resistance  
As for many antibiotics, the resistance goes through two main mechanisms: reduction of the 
intrabacterial concentration of the antibiotic and alteration of its target enzymes. For the latter 
mechanism, it is in fact mutations in genes encoding DNA gyrase and topoisomerase IV. This type 
of mutation is stable and spread easily in the bacterial environment. The clinical resistance appears 
according to a mechanism in step of staircase by accumulation of several genetic mutations. This 
can induce class resistance to all quinolones, or only certain family molecules.  
Here again, the presence of a methoxy group in the 8-position, as for moxifloxacin and 
gatifloxacin, is important since it reduces the probability of selection of mutant resistant [15-18]. 
As for reducing the concentration of antibiotics in the bacteria, it can involve several mechanisms, 
including changes in the external bacterial membrane, such as the modification of protein 
structures called porins, which provide a part of the exchanges between the outside and the outside. 
inside the bacteria. Since these exchange systems are not specific for the molecules transported, 
the acquisition of this type of resistance can also lead to a reduction in sensitivity to other classes 
of antibiotics, notably carbapenems [15].  
The reduction of the concentration of quinolones in the bacterium can also be the consequence 
of the increase in its output, by a so-called efflux system. This mechanism can either make the 
bacterium resistant to the antibiotic itself if it is very powerful, or allow the bacterium to survive 
in a suboptimal concentration of antibiotics, which ultimately promotes the appearance of genetic 
mutations in the body. made of a major pressure of antibiotic selection then playing at its 
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maximum efficiency. It is therefore in all cases a mechanism promoting resistance to quinolones, 
and its low specificity tends to allow the emergence of multiresistance. 
Finally, quinolone resistance can also be transmitted by plasmids. However, this phenomenon 
well described in Klebsiella sp. and Escherichia coli appear to be rare for other bacterial families, 
except in certain geographic areas such as East Asia [19]. 
4. Fluoroquinolones toxicity 
For decades, administrative organizations and the therapeutic calling were doubtful that a brief 
course of anti-microbials might have such an obliterating, long-term affect. But after diligent 
campaigning by quiet bunches, states of mind started to alter in 2008, when the FDA declared the 
primary of what would be an arrangement of solid alarms around the side impacts of 
fluoroquinolone drugs, counting ligament crack and irreversible nerve harm [20]. In 2016, the 
organization acknowledged the presence of a possibly changeless disorder, and prescribed that the 
drugs be saved for genuine diseases [21]. 
Fluoroquinolones are important anti-microbials, and secure for most individuals. However, 
they are so broadly endorsed that their side impacts might have hurt hundreds of thousands of 
individuals say researchers who are working with patients [21]. Fluoroquinolone harmfulness 
gives a compelling illustration of a rising understanding that anti-microbials don’t fair hurt 
organisms but they can extremely harm human cells as well [23]. 
5. Conclusions 
Fluoroquinolone resistance isn't straightforward and our understanding of the numerous 
components of resistance, the biological effect of each on the have strain, and the transaction 
between diverse instruments has expanded drastically in later a long time. Additionally, the long-
term destiny of distinctive strains of distinctive species with differing combinations of 
fluoroquinolone-resistance changes is greatly difficult to predict. Clearly there's no ‘one-size-fits-
all’ reply to how fluoroquinolone resistance will influence the advancement of pathogens and wide 
conclusions based on one life form may not be significant to all. What is getting to be progressively 
clear is that resistance to fluoroquinolones can be chosen beneath a wide extend of particular 
conditions and in certain circumstances safe strains may illustrate a fitness advantage over 
antibiotic-sensitive strains, indeed within the nonappearance of fluoroquinolone pressure. 
Fluoroquinolone resistance is common and typically likely to be related to the science of 
resistance as well as a coordinate reaction to medicate weight. Subsequently, minimizing 
resistance will not be as straightforward as confining the utilize of these agents. 
However, this antibiotic linked to toxicity that's left many chronically ill, should be used as 
last resort only. 
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